Table 3.
Anatomic and hemodynamic measurements at week 4
| Sham + Veh | Sham + TNFR1 shRNA | Sham + Con shRNA | HF + Veh | HF + TNFR1 shRNA | HF + Con shRNA | |
|---|---|---|---|---|---|---|
| Body weight, g | 355 ± 2 | 351 ± 3 | 352 ± 4 | 348 ± 9 | 350 ± 5 | 352 ± 6 |
| LV/body weight, mg/g | 2.44 ± 0.15 | 2.39 ± 0.11 | 2.40 ± 0.09 | 2.35 ± 0.11 | 2.46 ± 0.08 | 2.40 ± 0.07 |
| Right ventricle/body weight, mg/g | 0.52 ± 0.03 | 0.51 ± 0.03 | 0.51 ± 0.02 | 0.90 ± 0.06* | 0.69 ± 0.05* † | 0.91 ± 0.07* |
| Lung/body weight, mg/g | 4.26 ± 0.37 | 4.23 ± 0.15 | 4.22 ± 0.19 | 9.07 ± 0.95* | 6.67 ± 0.45* † | 8.98 ± 0.47* |
| Heart rate, beats/min | 362 ± 11 | 366 ± 7 | 360 ± 6 | 368 ± 7 | 370 ± 15 | 369 ± 10 |
| Systolic blood pressure, mmHg | 126 ± 2 | 122 ± 3 | 128 ± 2 | 108 ± 3* | 110 ± 3* | 106 ± 4 |
| Diastolic blood pressure, mmHg | 90 ± 2 | 89 ± 4 | 92 ± 4 | 87 ± 3 | 86 ± 3 | 84 ± 4 |
| LV peak systolic pressure, mmHg | 119 ± 2 | 118 ± 3 | 120 ± 3 | 99 ± 2* | 104 ± 3* | 99 ± 3* |
| LV end-diastolic pressure, mmHg | 3.38 ± 0.39 | 3.44 ± 0.41 | 3.44 ± 0.34 | 16.07 ± 0.89* | 12.74 ± 0.88* † | 16.51 ± 1.15* |
| LV dP/dtmax, mmHg/s | 9080 ± 350 | 9015 ± 285 | 9100 ± 306 | 6022 ± 215* | 7362 ± 229* † | 6081 ± 231* |
Values are expressed as means ± SE; n = 6 animals/group for anatomic measurements and n = 7 animals/group for hemodynamic measurements. Sham, sham operation; Veh, vehicle; Con, control; HF, heart failure; LV, left ventricular. Data were analyzed with two-way ANOVA followed by multiple-comparison tests [body weight: HF effect, F(1, 30) = 0.37, P = 0.55, and treatment effect, F(2, 30) = 0.04, P = 0.96; LV/body weight: HF effect, F(1, 30) = 0.006, P = 0.94, and treatment effect, F(2, 30) = 0.04, P = 0.95; right ventricle/body weight: HF effect, F(1, 30) = 70, P < 0.0001, and treatment effect, F(2, 30) = 3.67, P = 0.04; lung/body weight: HF effect, F(1, 30) = 95, P < 0.0001, and treatment effect, F(2, 30) = 3.69, P = 0.04; heart rate: HF effect, F(1, 36) = 0.57, P = 0.46, and treatment effect, F(2, 36) = 0.07, P = 0.94; systolic blood pressure: HF effect, F(1, 36) = 35, P < 0.0001, and treatment effect, F(2, 36) = 0.04, P = 0.96; diastolic blood pressure: HF effect, F(1, 36) = 3.18, P = 0.08, and treatment effect, F(2, 36) = 0.05, P = 0.95; LV peak systolic pressure: HF effect, F(1, 36) = 92, P < 0.0001, and treatment effect, F(2, 36) = 0.77, P = 0.47; LV end-diastolic pressure: HF effect, F(1, 36) = 367, P < 0.0001, and treatment effect, F(2, 36) = 3.76, P = 0.03; LV dP/dtmax: HF effect, F(1, 36) = 133, P < 0.0001, and treatment effect, F(2, 36) = 3.41, P = 0.04].
P < 0.05, vs. the Sham + Veh group.
P < 0.05, HF + TNFR1 shRNA group vs. HF + Veh group.